Entera Bio Ltd. Net Income Common

Net Income Common of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Income Common growth rates and interactive chart. Net income to common (NIC), also called net profit to shareholders, is calculated as sales minus cost of goods sold, selling, general and administrative expenses, operating expenses, depreciation, interest, taxes, and other expenses incuding preferred dividends. It is a useful number for investors to assess how much revenue exceeds the expenses of an organization.


Highlights and Quick Summary

  • Net Income Common for the quarter ending June 29, 2020 was $-3.19 Million (a 9.32% increase compared to previous quarter)
  • Year-over-year quarterly Net Income Common increased by 6.55%
  • Annual Net Income Common for 2019 was $-10.8 Million (a 4.77% increase from previous year)
  • Annual Net Income Common for 2018 was $-10.3 Million (a -7.98% decrease from previous year)
  • Twelve month Net Income Common ending June 29, 2020 was $-12.5 Million (a 17.02% increase compared to previous quarter)
  • Twelve month trailing Net Income Common increased by 25.42% year-over-year
Trailing Net Income Common for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-12.5 Million $-10.7 Million $-10.8 Million $-10 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Income Common of Entera Bio Ltd.

Most recent Net Income Commonof ENTX including historical data for past 10 years.

Interactive Chart of Net Income Common of Entera Bio Ltd.

Entera Bio Ltd. Net Income Common for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.19 $-2.92
2019 $-3.44 $-2.99 $-1.37 $-3.0 $-10.8
2018 $-2.65 $-5.07 $1.56 $-4.16 $-10.3
2017 $-11.2

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.